About us

The cost of healthcare is rising yearly due to high demands on health prevention and diagnosis, unmet patient needs, an increase of an older population, costs of new drug development, an increase in chronic diseases and other factors.

The pharmaceutical and healthcare industries are complex. These industries need the cooperation of multiple stakeholders to comply with highly regulated environments that ultimately seek to ensure patients’ safety. All aspects of the production of new medicines including, among other things, clinical trials, manufacturing and distribution, have strict regulatory and ethical guidelines to which both industries must adhere to.

The complexity and the lack of transparency, coordination and trust are big challenges in this context. This is where blockchain could provide solutions by reducing the costs of healthcare, drug development processes, and time of delivery of the drugs to patients with unmet needs. The PharmaLedger consortium will drive early adoption of disruptive blockchain-based digitisation technology, with key industry participants joining forces to build a comprehensive solution for improving the quality of healthcare. The pharmaceutical industry has come together in the PharmaLedger consortium in order to explore blockchain technology’s application to these real-world challenges. Specifically, supply chain, health data exchange in the marketplace and clinical trials.





European Blockchain Convention


The European Blockchain Convention is considered to be one of the main Blockchain Conferences in Europe. Throughout the conferences, their mission is to provide relevant and inspiring content in collaboration with the brightest experts in the Blockchain world, while also facilitating an exclusive networking environment where all participants meet to form business relationships.

The EBC is made up of two Editions throughout the year:
The Iberian Edition in Barcelona, and the Nordic Edition in Copenhagen.




LogiPharma is the world’s leading pharma supply chain event bringing representation from each of the top 15 global pharma companies. This year’s virtual edition aims to optimise supply chain value while saving costs and reducing risk while remaining compliant, providing the only opportunity to learn from and network with the world’s largest pharma supply chain community at the most critical time facing the industry.

At LogiPharma Virtual 2021, supply chain leaders will reveal insights on: How the industry is preparing for Covid-19 vaccine distribution whilst ensuring the integrity of pre-existing supply chains; Leveraging tech transformation to drive end to end, digitally enabled, patient-centric supply chains; and how to fundamentally redesign your supply chain to overcome the challenges of Covid-19 disruption, meet the demands of personalised medicines, and thrive as an originator with a competitive advantage.

This year, pharma professionals can secure their tickets for free.




Sanofi joined the Pharmaledger consortium in September 2021 in order to empower patients, increase digital trust among healthcare stakeholders, and support medicinal drug traceability and data privacy using a scalable blockchain platform. This platform is validated through reference use cases in supply chain, clinical trials and health data.

We are actively contributing to making the use case of finished goods traceability a success by implementing the blockchain infrastructure in the Sanofi environment and doing real-life experimentation. Also, we are making progress internally to join the Anti-counterfeiting and Electronic Product Information use cases to empower patients.

Sanofi’s vocation is to support those facing health difficulties. A global biopharmaceutical company specializing in human health, we prevent diseases with our vaccines and offer innovative treatments. We support both those suffering from rare diseases and the millions of people suffering from a chronic disease. Sanofi and its more than 100,000 employees in 100 countries transform scientific innovation into health solutions around the world.


Zuellig Pharma


Zuellig Pharma joined the PharmaLedger consortium in September 2021 to work toward interoperability and set up a multi-cloud infrastructure (WP3) with all PharmaLedger participants. Leveraging our in-house team’s blockchain expertise, we will help participants establish production-grade enterprise nodes, connecting members effectively so all can contribute to making healthcare more accessible.

In 2020, Zuellig Pharma launched the first live production-grade blockchain in Asia across four key markets and has since uploaded more than two million products to the blockchain. This enables Zuellig Pharma to contribute to business use cases (WP1) including track and trace, sales rechannelling and cold chain monitoring, as it has done with clients such as MSD.

Zuellig Pharma is one of the largest healthcare services groups in Asia with a history going back 100 years and a mission to make healthcare more accessible. Providing world-class distribution, digital and commercial services to support the growing healthcare needs in 13 markets, the business serves over 350,000 medical facilities and more than 500 clients, including the top 20 pharmaceutical companies in the world.




Since February 2022 Takeda has partnered with the PharmaLedger consortium with the objective to help develop a scalable, widely trusted blockchain platform which allows patients, health care providers, supply chain partners, pharmacists, manufacturers and regulators to connect, collaborate and further digitize healthcare systems globally.

We are co-leading two major workstreams with the current focus on the ePI (electronic product information) use case. We distribute around 500 million pieces of product information each year – product summaries for HCPs, labels, and packaging leaflets for patients. The PharmaLedger consortium offers us a collaborative, scalable platform to securely share this information digitally, which leads to saving resources and avoiding waste over the long-term.

ePI is just the start. We are looking at other use cases, including anti-counterfeiting.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, and guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. Takeda’s over 45,000 employees help provide patients with life-changing treatments in more than 80 countries.


Sign up for our monthly newsletter to stay up to date on all our information, news and activities in just one email a month! Unsubscribe at any time.


Sign up for our monthly newsletter to stay up to date on all our information, news and activities in just one email a month! Unsubscribe at any time.